hotspot -WSS

hotspot

author：entertainment 2025-09-28 00:52:55 - browse：36

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Mass General, Mayo Clinic look to monetize custom

Wikipedia

WSS

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Election results set back Medicaid expansion plans

High breast density mammograms need follow

Pennsylvania man bitten on the head by bear during attack in his garage

FDA endorses new sterilization method for medical devices

With heat waves through August, officials warn of health risks

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Activists slam private health insurers over coverage restrictions

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

The cancer drug shortage isn’t new — and neither are the solutions

Google's generative AI to analyze medical images — and talk to docs

How one medical school became remarkably diverse

Dana Farber says 6 studies to be retracted and 31 corrected

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Update the Apgar Score to remove skin color

The high cost of giving birth even with insurance

Judge in Trump's classified documents case questions use of out

focus

Kansas bar where gunfire wounded 9 last month closes permanently

Failure, not just success, should guide future doctors

CVS is on a mission to consolidate health care. Will it work?

HPV vaccine, cervical cancer study delivers historic results

Flu vaccine reformulation won't be easy, manufacturers warn

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Wikipedia

focus

Wikipedia

focus